 Journal
Articles (Published)
2010
51. Lalani S, Peschken C, Pope J, Clinical Features and Prognosis of Late Onset
SLE: Results from the 1000 Faces of Lupus Study. J Rheumatol. 2010 Jan;37(1):38-44.
Epub 2009 Dec 15.
50. Aghdassi E, Morrison S, Landolt-Marticorena C, Su J, Pineau
C, Gladman D, Urowitz M. B., Pope J, Peschken C, CaNIOS LuNNET & HIPP Investigators,
DaCosta D, Wither J, Fortin PR. The Use of Micronutrient Supplements is not Associated
with Better Quality of Life & Disease Activity in Canadian Patients with Systemic
Lupus Erythematosus. Journal of Rheumatology. 2010 Jan;37(1):87-90. Epub 2009 Dec
1.
49. Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman D, Urowitz M.B., Lou W,
Fortin PR. The Protective Effect of Antimalarial Drug on Thrombovascular Events
in Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2010 March 62(3):863-8.
48. Mittoo S, Gelber A, Hitchon C, Silverman ED, Pope JE, Fortin PR, Pineau C, Smith
CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M,
Tucker L, Petty R, Canadian Network For Improved Outcomes In Systemic Lupus Erythematosus
(CaNIOS), Peschken CA. Systemic Lupus Erythematosus-Related Serositis is Associated
with Ribonucleoprotein Antibody: Finding from a Multi-Ethnic, Multi- Center Canadian
Cohort . J Rheumatol. 2010 Feb 37(4):747-53, 2010.
47. Yip J, Aghdassi E, Su J,
Lou W, Reich H, Bargman J, Scholey J, Gladman D, Urowitz MB, and Fortin PR. Serum
Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus.
Journal of Rheumatology 2010 Aug 1: 37(8):1667-72.
46. Jung H, Bobba R, Su J, Sarabi
Z, Gladman D, Urowitz MB, Lou W, Fortin PR. Antimalarials and Thromboembolic Disease
in SLE. Arthritis and Rheumatism (In Press – Manuscript No. ar-10-0479)
45. Cooper
G, Wither J, Bernatsky S, Claudio J, Clarke A, Rioux J, CaNIOS Collaborators, Fortin
PR. Occupational and Environmental Exposures and Risk of SLE: Silica, Sunlight,
Solvents. Rheumatology 2010; doi: 10.1093/rheumatology/keq214. (SA)
2009
44. Neville
C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Fortin PR (*Neville C and
Rauch J contributed equally to this research). Antiphospholipid antibodies predict
imminent vascular events independently from other risk factors in a prospective
cohort. Thrombosis and Haemostasis. 2009;101(1):100-7 PMID: 19132195 (SA).
43. Peschken
CA, Katz S, Silverman E, Pope J, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman
D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M, CaNIOS Investigators. Lupus
in Canada: The 1000 Canadian Faces of Lupus Project Baseline Description of the
Cohort. (in press) (J Rheum)
42. Law G, Pope J, Lalani S, Silverman E, Cooper G,
Fortin PR, Zummer M, Smith CD, Petty R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga
A, Chedéville G, Hudson M, CaNIOS Investigators; Peschken, C. Barriers to Healthcare
in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) patients: Patient
and Physician Perceptions. (in press) (Clinical Medicine: Arthritis and Musculoskeletal
Disorders).
41. Colangelo K, Pope J, Peschken, C. The minimally important difference
(MID) for patient reported outcomes in systemic lupus erythematosus (SLE) including
the HAQ-DI, pain, fatigue and SF-36. J Rheumatol. 2009 Oct;36(10):2231-7. Epub 2009
Sep 1.
40. Baker K., Pope J., Fortin PR, Silverman E., Peschken C; 1000 Faces of
Lupus Investigators; CaNIOS (Canadian Network for Improved Outcomes in SLE). Work
Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio-
demographic and Disease Related Factors. Lupus. 2009 Dec;18(14):1281-8. Epub 2009
Oct 23. PMID: 19854811 [PubMed - indexed for MEDLINE]
39. Yuen SY, Mok MY, Wong
WS, .Silverman ED, Pope JE, Fortin PR, Smith CD, Zummer M, Hudson M, Pineau C. Clarke
A, Bernatsky S, Urowitz M, Gladman D, Canadian Network For Improved Outcomes In
Systemic Lupus Erythematosus (CaNIOS), Peschken CA. Systemic Lupus Erythematosus:
A Comparative Study of Clinical Manifestations and Damage in Two Chinese Populations.
Journal of Rheumatology. 2009 November; 36(11):2577-78.
2008
38. Graham DS, Vyse
TJ, Fortin PR, Montpetit A, Cai YC, Lim S, McKenzie T, Farewell L, Rhodes B, Chad
L, Hudson TJ, Sharpe A, Terhorst C, Greenwood CM, Wither J, Rioux JD. Association
of LY9 in UK and Canadian SLE families. Genes Immun. 2008 Mar;9(2):93-102. Epub
2008 Jan 24.PMID: 18216865.
37. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz
M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman
A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi
S, Ramsey-Goldman R, Clarke AE. The relationship between cancer and medication exposures
in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9.
Epub 2007 Jun 1. PMID: 17545189 [PubMed - indexed for MEDLINE]
36. Hudson M, Bernatsky
S, Taillefer S, Fortin PR, Wither J, Canadian Scleroderma Research Group (CSRG);
Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS),
Baron M. Patients with systemic autoimmune diseases could not distinguish comorbidities
from their index disease. J Clin Epidemiol. 2008 Mar 12; [Epub ahead of print] PMID:
18342489 [PubMed - as supplied by publisher]
35. Graham RR, Cotsapas C, Davies L,
Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge
RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Cunninghame – Graham D, Wong AK,
Vyse TJ, Daly MJ, Altshuler D, Moser KL and Gaffney PK. A Genome-Wide Scan Identifies
Association of Tumor Necrosis Factor Alpha Inducible Protein 3 (TNFAIP3/A20) with
Systemic Lupus Erythematosus. Nat Genet. 2008; Aug 1. [Epub ahead of print] PMID:
18677312.
34. Cooper GC, Wither JE, McKenzie T, Claudio J, CaNIOS GenES Investigators,
Fortin PR. The prevalence and accuracy of self-reported history of eleven autoimmune
diseases. J Rheumatol. 2008:35(10):1-4.
33. Fortin PR, Abrahamowicz M, Ferland D,
Lacaille D, Smith CD, Zummer M, and the Canadian Network for Improved Outcomes in
Systemic Lupus Erythematosus. Steroid- Sparing Effects of Methotrexate in Systemic
Lupus Erythematosus. Arthritis Rheum. 2008 Dec 15;59(12):1796-804 PMID: 19035431.
32. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T., Su J,
Gladman D, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha
signature and longitudinal changes in disease activity in Systemic Lupus Erythematosus.
Ann Rheum Dis. 2008 Sep 4. [Epub ahead of print] PMID: 18772188.
31. Wither, J.,
Cai, Y.C., Lim, S., McKenzie, T., Claudio, J.O., Cooper, G.S., Hudson, T.J., Greenwood,
C.M.T., Gladman, D., Pope, J., Pineau, C., Smith, C.D., Hanly, J., Peschken, C.,
Boire, G., CANIOS Investigators, and Fortin, PR. Reduced proportions of NKT cells
are present in the relatives of lupus patients and are associated with autoimmunity.
Arthritis Res Ther. 2008; 10(5):R108. Epub 2008 Sept. 10. PMID: 18783591.
2007
30.
Bin J, Bernatsky S, Gordon C, Boivin JF, Ginzler E, Gladman D, Fortin PR, Urowitz
M, Manzi S, Isenberg D, Rahman A, Petri M, Nived O, Sturfeldt G, Ramsey-Goldman
R, Clarke AE. Lung cancer in Systemic lupus erythematosus. Lung Cancer. 2007 Jun;56(3):303-6.
PMID: 17291624.
29. Bernatsky S, Ramsey-Goldman R, Boivin J-F, Joseph L, Rajan R,
Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy E,
Barr S, Gordon C, Bae S-C, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley M-A,
Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal J-L, Zummer M, Hanly J, Ensworth
S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A. An international cohort
study of cancer in systemic lupus erythematosus (SLE). Arthritis and Rheumatism
(accepted for publication)
28. Bernatsky S, Ramsey-Goldman R, Isenberg D, Rahman
A, Dooley MA, Sibley J, Boivin JF, Joseph L, Armitage J, Zoma A, Clarke A. Hodgkin’s
lymphoma in systemic lupus erythematosus. Rheumatology (Oxford). 2007 May; 46(5):
830-2. Epub 2007 Jan 25. PMID: 17255135
27. Bernatsky S, Boivin JF, Joseph L, Gordon
C, Urowitz M, Gladman D, Ginzler E, Fortin P, Bae SC, Barr S, Isenberg D, Rahman
A, Petri M, Alarcon G, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M, Manzi
S, Edworthy S, Ramsey-Goldman R, Clarke A. The relationship between cancer and medication
exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2007
Jun 1; PMID: 17545189.
2006
26. Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman
R, Clarke AE, Pineau CA. Cancer screening in partients with systemic lupus erythematosus.
J Rheumatol. 2006 Jan;33(1):45-9. Epub 2005 Dec 1. PMID: 16331804 [PubMed - indexed
for MEDLINE
25. Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG,
Senecal JL, Zummer M, Edworthy S, Sibley J, Pope J, Ensworth S, Ramsey-Goldman R,
Hanly JG. Mortality related to cerebrovascular disease in systemic lupus erythematosus.
Lupus. 2006;15(12):835-839.
24. Bernatsky S, Clarke A, Pope J, Hanly JG, Smith CD,
Peschken C, Rich E, Boire G, Fortin PR. Malignancy prevalence in the first-degree
relatives of persons with systemic lupus erythematous: a pilot study. Lupus. 2006;15(10):695-6.
No abstract available. PMID: 17120599.
23. Bernatsky S, Boivin JF, Joseph L, Manzi
S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC,
Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon
G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley
J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality
in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. PMID: 16868977.
2005
22. Bernatsky S, Ramsey-Goldman R, Boivin J-F, Joseph L, Rajan R, Zoma A, Manzi
S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy E, Barr S, Gordon
C, Bae S-C, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley M-A, Steinsson K, Nived
O, Sturfelt G, Alarcon G, Senecal J-L, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy
H, McCarthy T, St. Pierre Y, Clarke A. An international cohort study of cancer in
systemic lupus erythematosus (SLE). Arthritis and Rheumatism 2005;52(5):1481-90.
21. Bernatsky S, Boivin J-F, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman DD,
Fortin PR, Gordon C, Barr S, Edworthy S, Bae S-C, Petri M, Sibley J, Isenberg D,
Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcón G, Hanly J, Sturfelt C, Nived
O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke
A, Ramsey- Goldman R. Race/Ethnicity and cancer occurrence in systemic lupus erythematosus.
Arthritis and Rheumatism. 2005;53(5):781-784.
20. Bernatsky S, Boivin JF, Joseph
L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M,
Edworthy S, Barr S, Gordon C, Bae SC Sibley J, Isenberg D, Rahman A, Aranow C, Dooley
MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J,
Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke
A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis
Rheum. 2005 May;52(5):1481-90. PMID: 15880596
19. Bernatsky S, Ramsey-Goldman R,
Rajan R, Boivin J-F, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler
E, Urowitz M, Gladman DD, Fortin PR, Edworthy S, Barr S, Gordon C, Bae S-C, Steinsson
K, Sturfelt C, St. Pierre Y, Clarke A. Non-Hodgkin’s lymphoma in systemic lupus
erythematosus. Ann Rheum. Dis. 2005;64:1507-1509.
18. Bernatsky S, Ramsey-Goldman
R, Clarke AE. Revisiting the issue of malignancy risk in systemic lupus erythematosus.
Curr Rheumatol Rep. 2005 Dec;7(6):476-81. Review. Erratum in: Curr Rheumatol Rep.
2006 Apr;8(2):iii. PMID: 16303109.
17. Bernatsky S, Clarke A, Abrahamowicz M, Neville
C, Karp I, Pineau CA. A comparison of prospective and retrospective evaluations
of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology
Damage Index for systemic lupus erythematosus. J Rheumatol. 2005 May;32(5):820-3.
PMID: 15868615
2004
16. Bernatsky S, Clarke A, Ramsey-Goldman R, Boivin JF, Joseph
L, Rajan R, Manzi S. Breast cancer stage at time of detection in women with systemic
lupus erythematosus. Lupus. 2004;13(6):469-72. PMID: 15303575.
15. Bernatsky S,
Ramsey-Goldman R, Gordon C, Joseph L, Boivin JF, Rajan R, Allen A, Moore AD, Leung
MH, Clarke A. Factors associated with abnormal Pap results in systemic lupus erythematosus.
Rheumatology (Oxford). 2004 Nov;43(11):1386-9. Epub 2004 Jul 27. PMID: 15280571
14. Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin JF, Rajan R, Moore
AD, Leung MH, Allen A, Gordon C. Hormonal exposures and breast cancer in a sample
of women with systemic lupus erythematosus. Rheumatology (Oxford). 2004 Sep;43(9):1178-81.
Epub 2004 Jun 29. PMID: 15226516
2003
13. Edworthy SM, Dobkin PL, Clarke A, et al.
Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus.
J Rheumatol 2003;30(5):1011-1016.
12. Yen JC, Abrahamowicz M, Dobkin PL, Clarke
AE, Battista RN, Fortin PR. Determinants of discordance between patients and physicians
in their assessment of lupus disease activity. Journal of Rheumatology. 2003 Sep;30(9):1967-76.
11. Bernatsky S, Ramsey-Goldman R, Boivin JF, Joseph L, Moore AD, Rajan R, Clarke
A. Do traditional Gail model risk factors account for increased breast cancer in
women with lupus? J Rheumatol. 2003 Jul;30(7):1505-7. PMID: 12858448
2002
10. Dobkin
PL, Da Costa D, Joseph L, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile JM,
Beaulieu A, Zummer M, Senécal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino
A, Gladman D, St-Pierre Y, Clarke AE. Counterbalancing patient demands with evidence:
Results from a Pan-Canadian randomized clinical trial of brief supportive- expressive
group psychotherapy for women with systemic lupus erythematosus. Annals of Behavioural
Medicine. 2002;24(2):88-99.
9. Chang E, Abrahamowicz M, Ferland D, Fortin PR. CaNIOS
Investigators. Comparison of the responsiveness of lupus disease activity measures
to changes in systemic lupus erythematosus activity relevant to patients and physicians.
Journal of Clinical Epidemiology. 2002;55(5):488-497.
8. Chang ER, Abrahamowicz
M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness
of two lupus disease activity measures, according to patients’ or physicians’ evaluations
of recent lupus activity. J Rheumatol 2002;29(11):2350-2358.
7. Bernatsky S, Boivin
JF, Joseph L, St Pierre Y, Moore A, Rajan R, Clarke A. Prevalence of factors influencing
cancer risk in women with lupus: social habits, reproductive issues, and obesity.
J Rheumatol. 2002 Dec;29(12):2551-4. PMID: 12465150.
6. Bernatsky S. Discussion
on inflammatory bowel disease is not associated with an increased risk of lymphoma.
Gastroenterology. 2002 Aug;123(2):653. PMID: 12145829.
5. Bernatsky S, Clarke A,
Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep.
2002 Aug;4(4):351-8. Review. PMID: 12126588.
4. Isenberg D, Ramsey-Goldman R, Clarke
A, Bernatsky S; SLICC Group. Systemic Lupus International Collaborating Clinics.
Lupus and malignancy. Lupus. 2002; 11 (3):199. PMID: 11999888
2001
3. Dobkin PL,
Da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile JM, Senécal J-L, Goulet J- R,
Choquette D, Rich E, Beaulieu A, Cividino A, Ensworth S, Smith D, Zummer M, Gladman
D, Clarke AE. Living with lupus: a prospective pan-Canadian study. J Rheumatol 2001;
28(11):2442-2448.
2. Dobkin PL, Da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile
JM, Senecal JL, Goulet JR, Choquette D, Rich E, Beaulieu A, Cividino A, Ensworth
S, Smith D, Zummer M, Gladman DD, Clarke AE. Living with lupus: A prospective pan-Canadian
study. Journal of Rheumatology. 2001;28(11):2442-2448.
1995 - 2000
1. Ferland D,
Fortin PR. Recruitment strategies in superiority trials in SLE: lessons from the
study of methotrexate in lupus erythematosus (SMILE). Lupus 1999;8:606-611.
Manuscripts
In Press
7. Zhang W, Aghdassi E, Reich HN., Su J, Lou W, Landolt-Marticorena C,
Gladman D, Urowitz M, Scholey J, Fortin PR. Glomerular Filtration Rate Predicts
Arterial Events in Women with Systemic Lupus Erythematosus. Rheumatology (In Press
– September 2010)(RHE-10-0713.R1)
6. Burdarf ML, Goyette P, GenES Investigators,
Boucher G, Lian J, Graham RR, Claudio JO, Hudson T, Barr SG, Boire G, Clarke AE,
Gladman D, Hanly J, Peschken C, Pope JE, Rich E, Smith CD, Zummer M, Fortin PR,
Wither J, Rioux JD. A targeted association study in Systemic Lupus Erythematosus
(SLE) identifies novel risk alleles, and replicates known susceptibility alleles.
Genes and Immunity (In Press - April 2010)
5. Bernatsky S, Peschken C, Fortin PR,
Urowitz MB, Gladman DD, Pope E, Hudson M, Zummer M, Smith D, Arbillaga H, Clarke
A. Medication Use in Systemic Lupus. Journal of Rhematology (In Press - 2010-0414.R1)
(June 2010)
4. Cooper G, Wither J, Bernatsky S, Claudio J, Clarke A, Rioux J, CaNIOS Collaborators,
Fortin PR. Occupational and Environmental Exposures and Risk of SLE: Silica, Sunlight,
Solvents. Rheumatology 2010; doi: 10.1093/rheumatology/keq214.
3. Bernatsky S, Lix, L, Hanly J, Fortin PR, Badley E, Peschken C, Pineau C, Hudson
M, Clarke A, Smith M, Bélisle P, Lagace C, Joseph L. Surveillance of Systemic Autoimmune
Rheumatic Diseases Using Administrative Data. Rheumatol Int. (In Press – PMID: 20665025)(July
28, 2010).
2. Aghdassi E, Ma D WL, Morrison S, Hillyer L M, Clarke S, Gladman DD,
Urowitz MB, Fortin PR. Alteration in Circulating Fatty Acid Composition in Patients
with Systemic Lupus Erythematosus: A Pilot Study. Journal of Parenteral and Enteral
Nutrition (In Press – Manuscript ID JPEN-2010-03-051)(August 2010)
1. Touma Z.,
Gladman DD, Tulloch-Reid D., Toloza S., Ibanez D., Fortin PR, Urowitz MB. Burden
of Autoantibodies and Association with Disease Activity and Damabe in Systemic Lupus
Erythematosus. Clinical and Experimental Rheumatology (In Press – CER 73509. July,
2010)
Books
1. Lupus: the disease with a thousand faces. Your Personal Health Series.
Eds. Jean-Luc Senécal and Sasha Bernatsky. Key Porter Books. 2004. (Coll).
Abstracts
(Published)
2010
111. Aghdassi E, Ma D.W., Morrison S, Hillyer L.M., Gladman D.D.,
Urowitz M.B., Fortin PR. Alteration in Circulating Fatty Acid Composition in Patients
with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp.
1-185.
110. Jeyalingam T., Su J., Brown P.E., Peschken C.A., Pope J.E., CaNIOS Investigators
and Fortin PR. Distance to Lupus Centre and Health Care Barriers in Systemic Lupus
Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
109. Dieude M, Correa
J, Neville C, Pineau C, Levine J, Subang R, Landolt-Marticorena C, Su J, Kassis
J, Solymoss S, Fortin PR and Rauch J. Autoantibodies to Heat Shock Protein 60 Are
Associated with Arterial Vascular Events in Patients with Anti-Phospholipid Antibodies.
Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
108. Yip J., Aghdassi E., Su J.,
Lou W., Reich H., Bargman J., Scholey J., Gladman D.D., Urowitz M.B., Fortin PR.
Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus
(SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1- 185.
107. Zhang W, Aghdassi E,
St-Pierre Y, Clarke AE., Landolt-Marticorena C., Morrison S, Su J., Reich H., Scholey
J., Herzenberg A., Pineau C., Pope J., Peschken C., CaNIOS Investigators, Wither
J. and Fortin PR. Health Care Cost in a Canadian Population of Patients With &
Without Lupus Nephritis. Accepted for poster presentation at the 2010 Lupus, June
2010; vol. 19, 1 suppl: pp. 1-185.
106. Aghdassi E, Cheung AM, Peeva V, Morrison
S, Cymet A, Su J, Neville C, Hewitt S, Morin S, McDonald-Blumer H, CaNIOS HIPP Investigators,
Pineau C, Pope J, Da Costa D, Fortin PR. Low Bone Mass in Female Patients with Systemic
Lupus Erythematosus (SLE): A Canadian Study. Lupus, June 2010; vol. 19, 1 suppl:
pp. 1-185.
105. Morrison S, Aghdassi E, Peeva V, Su J, Landolt-Marticorena C, Gladman
DD, Urowitz MB, Pineau C, Pope J, Peschken C, CaNIOS LuNNET Investigators, Wither
J and Fortin PR. Perceived Stress in Female Patients with Systemic Lupus Erythematosus
(SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
104. Jeyalingam T., Aghdassi
E., Su J., Clarke AE., Cooper GS., Rioux JD., Wither J., CaNIOS GENES-Investigators,
Fortin PR. Quality of Life of Patients With Systemic Lupus Erythematosus (SLE) and
Their Family Members. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
103. Jeyalingam
T., Su J, Brown P, Peschken C, Pope J, CaNIOS 1000 Faces Investigators, Fortin PR.
Distance to Lupus Centre and Health Care Barriers in Systemic Lupus Erythematosus.
Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
102. Peeva V, Aghdassi E, Su J, Gladman
DD, Urowitz MB., Landolt-Marticorena C, Yeo E, Fortin PR. Clinical Characteristics
and Quality of Life of Patients with Primary and Secondary Antiphospholipid Syndrome.
Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
101. Peeva V, Aghdassi E, Su J, Morrison
S, Cymet A, Harvey P, Neville C, Hewitt S, Pineau C, Pope J, Da Costa D, Fortin
PR. Cardiovascular Risk Factors in Patients with Systemic Lupus Erythematosus without
Past History of Cardiovascular Event. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
100. Zhang W, Aghdassi E, Reich HM, Su J, Lou W, Landolt-Marticorena C, Gladman
DD, Urowitz MB, Scholey JW and Fortin PR. Poor Renal Function In Patients with Systemic
Lupus Erythematosus (SLE) Predicts Cardiovascular Events. Lupus, June 2010; vol.
19, 1 suppl: pp. 1-185.
99. Bernatsky S, Peschken C, Urowitz MB, Gladman DD, Clarke
A, Pope J, Fortin PR, Pineau C, Zummer M, Smith CD, Arbillaga H, Hudson M, CaNIOS
1000 Canadian Faces of Lupus. Medication Use in Systemic Lupus Erythematosus. Lupus,
June 2010; vol. 19, 1 suppl: pp. 1-185.
98. Peeva V, Su J, Aghdassi E, Gladman DD,
Urowitz MB, Landolt-Marticorena C, Yeo EL, Fortin PR. Clinical Characteristics and
Quality of Life of Patients with Primary and Secondary Antiphospholipid Syndrome.
Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
97. Neville C, Rauch J, Kassis J,
Solymoss S, Joseph L, Belisle P, Fortin PR. Antiphospholipid Antibodies Predict
Future Arterial Events: Results from the Montreal Antiphospholipid Study (MAPS)
at Eleven Years of Follow Up. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
96.
Peeva V, Aghdassi E, Morrison S, Cymet A, Su J, Harvey P, Neville C, Hewitt S, Pineau
C, Pope J, Dacosta D, Fortin PR. Framingham Scores and Individual Cardiovascular
Disease (CVD) Risk Factors in Patients with Systemic Lupus Erythematosus (SLE) without
Past History of Cardiovascular Events. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-
185.
95. Aghdassi E, Cheung A.M., Peeva V, Morrison S, Cymet A, Su J, Neville C,
Hewitt S, Morin S, McDonald-Blumer H, CaNIOS Investigators, Pineau C, Pope J, Da
Costa D, Fortin PR. Low Bone Mass in Female Patients with Systemic Lupus Erythematosus
(SLE): A Canadian Study. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
94. Morrison
S, Aghdassi E, Peeva V, Su J, Landolt-Marticorena C, Gladman DD, Urowitz MB, Pineau
C, Pope J, Peschken C, Wither J, Fortin PR. Perceived Stress in Female Patients
with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp.
1-185.
93. Landolt-Marticorena C, Morrison S, Reich H, Aghadassi E, Hertzenberg
A, Scholey J, Gladman D, Urowitz MB, Fortin PR, Wither JE. Clinical Utility of Changes
in Cyto/Chemokines as Markers of Disease Activity in Systemic Lupus Erythematosus.
Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
92. Landolt-Marticorena C, Reich
H, Morrison S, Aghadassi E, Pineau C, Scholey J, Gladman D, Urowitz M, Hertzenberg
A, Fortin PR, Wither JE. Urinary cyto/chemokines correlates with renal histopathology
in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
91. Peschken CA, Silverman E, Pope JE, Fortin PR, Pineau CA, Tucker LB, Zummer M,
Hudson M, Urowitz M, Gladman DD, Clarke A, Bernatsky S, Chedeville G, Huber A, Ramsey
SE, Smith CD, Arbillaga H, CaNIOS 1000 Faces Investigators. Lupus in Asian Canadians:
The 1000 Canadian Faces of Lupus Study. Lupus, June 2010; vol. 19, 1 suppl: pp.
1-185.
90. Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Landolt-Marticorena C, Morrison
S, Su J, Reich H, Scholey J, Herzenberg A, Pineau C, Pope J, CaNIOS Investigators,
Wither J, Fortin PR. Health Care Cost in a Canadian Population of Patients with
and without Lupus Nephritis. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.
89.
Florica B., Su J., Aghdassi E., Gladman DD., Urowitz MB., Fortin PR.. Peripheral
Neuropathy in Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010;
vol. 19, 1 suppl: pp. 1-185.
88. Huang D., Aghdassi E., Su J, Fortin PR. The Prevalence
of Liver Abnormalities in Patients with Systemic Lupus Erythematosus. Lupus, June
2010; vol. 19, 1 suppl: pp. 1-185.
87. Bernatsky S, Ramsey-Goldman R, Gordon C,
Manzi S, Nived O, Bae SC, Ruiz-Irastorza G, Costenbader KH, Jacobsen S, Isenberg
D, Rahman A, Witte T, Sturfelt GK, Lee JL, Turnbull E , Clarke AE, Non-Hodgkin's
Lymphoma in Systemic Lupus 9th International Congress on Systemic Lupus Erythematosus,
Vancouver, BC, Canada. June, 2010
86. Borowoy A, Peschken C, Pope J on behalf of
1000 Faces of Lupus Investigators. CNS Lupus: The Prevalence and Antibodies Depend
on the Definition. Results from the 1000 Faces of Lupus Cohort. Submitted for presentation
at the American College of Rheumatology Annual Scientific Meeting, Atlanta, GA,
Nov. 7-11, 2010.
85. Lee J, Pope J, Peschken C on behalf of 1000 Faces of Lupus.
Hospitalization in Systemic Lupus Erythematosus (SLE): Incidence and Predictors
of Hospitalization in Systemic Lupus Erythematosus (SLE): Results from a Large Contemporary
Multi-Ethnic Cohort. Submitted for presentation at the American College of Rheumatology
Annual Scientific Meeting, Atlanta, GA, Nov. 7-11, 2010.
2009
84. Akhavan P., Neville
C., Su J., Kassis J., Solymoss S., Pineau C., Peschken C., Pope J., Boire G., Rauch
J., Fortin PR. Vascular Events in Systemic Lupus Erythematosus (SLE): Evaluation
of Thrombophilic Factors in a Multicentre Inception Cohort (ThromboFIL). Journal
of Rheumatology. 2009; 36:11; 2604-5. .
83. Aghdassi E., Morrison S., Landolt-Marticorena
C., Su J., Pineau C., Pope J., Peschken C., Gladman D., Urowitz M., CaNIOS LuNNET
Investigators, Wither J., Fortin PR. Quality of life in lupus patients with and
without renal involvement. Journal of Rheumatology. 2009; 36:11; 2563.
82. Aghdassi
E., Su J., Claudio J., Morrison S., Cymet A., Neville C., CaNIOS Investigators,
DaCosta D., Fortin PR. The Use of Micronutrient Supplements among Patients with
Systemic Lupus Erythematosus. Journal of Rheumatology. 2009; 36:11; 2583-4..
81.
Dhanhani A., Harvey P., Su J., Pineau C., Cymet A., DaCosta D., Fortin PR. The Excess
Of Endothelial Dysfunction in SLE is not Explained by Framingham Cardiac Risk Factors.
Journal of Rheumatology. 2009; 36:11; 2588..
80. Adams K., Landolt-Marticorena C.,
Unnithan T., Gladman D., Urowitz M., Fortin PR, Wither J. Circulating levels of
sVCAM, IP-10 and MCP-1 correlate with changes in disease activity in Systemic Lupus
Erythematosus. Journal of Rheumatology. 2009; 36:11; 2559.
79. Kim J., Aghadassi
E., Gladman D., Urowitz M., Fortin PR, and Wither J. Evidence for altered activation
of newly-emergent bone marrow-derived B cells in Systemic Lupus Erythematosus (SLE).
Accepted for poster presentation at the Canadian Rheumatology Association 64th Annual
Meeting and Scientific Program, Kananaskis, Alberta, February 18 -21, 2009.
78.
Colangelo K, Pope J, Peschken C, and Members of 1000 Faces of Lupus. The minimally
important difference for patient reported outcomes in SLE including pain, fatigue
and SF36. Accepted for poster presentation at the Canadian Rheumatology Association
64th Annual Meeting and Scientific Program, Kananaskis, Alberta, February 18 -21,
2009.
77. Baker K, Pope J, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD,
Petty, R. Tucker L, Albert L, Huber A, Ramsey S, Arbillaga H, Chedéville G, Hudson,
M, CaNIOS Investigators; Peschken C.. Work Disability in Systemic Lupus Erythematosus
is Prevalent and Predicted by Socio-demographic and Disease Related Factors: Results
from a Multi- Ethnic Cohort. Journal of Rheumatology. 2009; 36:11; 2559..
76. Yuen
SY, Mok MY, Wong WS , Pope J, Silverman E, Tucker L, Smith CD, Bernatsky S, Pineau
C, Zummer M, Chedeville G, Urowitz M , Gladman D, Clarke A, Fortin PR, Peschken
C. Systemic Lupus Erythematosus (SLE): A Comparative Study of Clinical Manifestations
and Damage in Two Chinese Populations. Journal of Rheumatology. 2009; 36:11; 2559.
.
75. Reich H, Landolt-Marticorena C, Boutros P C, Nasr S, Thomas D, Wither J, Yang
S, Su J, Aghdassi E, Gladman D, Urowitz MB, Fortin PR, Scholey JW and Herzenberg
AM. Tissue markers of injury in kidney biopsies of patients with lupus nephritis.
(Submitted to the American Society of Nephrology, June 2009).
74. Zhang W, Aghdassi
E, Reich H, Scholey J, Su J, Fortin PR. Baseline eGFR is Predictive of Cardiovascular
Diseases in Patients with Systemic Lupus Erythmatosus (SLE). Arthritis and Rheumatism.
2009;60(9suppl):1930.
73. Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle
P, Fortin PR. Antiphospholipid Antibodies Predict Future Arterial But Not Venous
Events at 11 Years of Follow-up. Arthritis and Rheumatism. 2009;60(9suppl):1214.
72. Landolt-Marticorena C., Reich H., Morrison S., Aghdassi E., Pineau C.A., Scholey
J., Gladman D., Urowitz M.B., Herzenberg A., Fortin PR and Wither J. Urine Cyto/Chemokines
Correlate with Renal Histopathology in Systemic Lupus Erythematosus. Arthritis and
Rheumatism. 2009;60(9suppl):564.
71. Cooper G, Wither J, Bernatsky S, Claudio J,
Clarke A, Rioux J, Paterson A, Fortin PR. New Directions for Environmental Research:
Results from the Genetic and Environmental Factors in Systemic Lupus Erythematosus
(GenES) Study. Arthritis and Rheumatism. 2009;60(9suppl):48.
70. Aghdassi E, Zhang
W, St-Pierre Y, Clarke A, Landolt C, Morrison S, Su J, Reich H, Herzenberg A, Scholey
J, Pineau C, Pope J, Peschken C.A., Wither J, Fortin PR. Health Care Resource Utilization
& Loss of Productivity in a Canadian Population of Patients with & without
Lupus Nephritis. Arthritis and Rheumatism. 2009;60(9suppl):705.
69. Bernatsky S.,
Peschken C, Fortin PR, Gladman D, Pope J, Clarke A, CaNIOS. Medication Use in Systemic
Lupus (SLE). Arthritis and Rheumatism. 2009;60(9suppl):939.
68. Landolt-Marticorena
C, Morrison S., Reich H, Aghdassi E, Herzenberg A, Scholey J, Gladman D, Urowitz
M, Fortin PR and Wither J. Clinical Utility of Changes in Cyto/Chemokines as Markers
of Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2009;60(9suppl):922.
67. Peschken CA, Pope J, Silverman E, Fortin PR, Pineau C, Zummer M, Urowitz M,
Gladman D, Hudson M, Tucker L, Chedeville G, Huber A, Bernatsky S, Clarke A, Smith
CD, Arbillaga H, Ramsey SE, and CaNIOS Investigators. Lupus in Asian Canadians:
The 1000 Canadian Faces of Lupus Study. Lupus, June 2010; vol. 19, 1 suppl: pp.
1-185.
66. Chang NH, Kim J, Aghdassi E, Urowitz MB, Gladman D, Fortin PR, Wither
J. Increased Proximal B Cell Receptor Signaling in the Naïve B Cell Population of
SLE Patients. Arthritis and Rheumatism. 2009;60(9suppl):112.
65. Tulloch-Reid D.M.,
Gladman D.D., Fortin PR, Herzenberg A., Cole E, Urowitz MB. The ISN/RPS Classification
of Renal Biopsy as a Determinant of Prognosis in a Prospective Lupus Cohort. Arthritis
and Rheumatism. 2009;60(9suppl):16341.
64. Bernatsky S, Ramsey-Goldman R, Oen K,
Rosenberg, Gordon C, Manzi S et al. Malignancy in Pediatric-Onset SLE. Arthritis
and Rheumatism 2009;60(S10): S280.
63. Bernatsky S, Ramsey-Goldman R, Urowitz M,
Gladman D, Ruiz-Irastorza G, Bae S et al. Effects of SLE Activity On Lymphoma Risk:
Preliminary Results of a Case-Cohort Study. Arthritis and Rheumatism 2009;60(S10).
62. Bernatsky S, Ramsey-Goldman R, Gordon C, Manzi S, Nived O, Bae S et al. Histology,
Prognostic Factors, Treatment, & Outcome in SLE Patients with Non-Hodgkin's
Lymphoma (NHL) ACR/ARHP Annual Scientific Meeting. Philadelphia, PA, USA. Oct. 2009.
2008
61. Carolina Landolt-Marticorena, Alla Lubovich, Gabriel Bonventi, Thulasi
Unnithan, Dafna Gladman, Murray Urowitz, Paul R. Fortin, and Joan E. Wither. Longitudinal
expression of interferon responsive elements in SLE patients does not correlate
with disease activity. Oral Presentation, CRA Annual Meeting. . March 5-8, 2008
in Mont Tremblant, Quebec
60. Carolina Landolt-Marticorena, Gabriel Bonventi, Yongchun
Cai, Thulasi Unnithan, Dafna Gladman, Murray Urowitz, Paul R. Fortin, and Joan.
E. Wither. Elevated BAFF levels correlate with altered B cell phenotypes in patients
with SLE. Oral Presentation, CRA Annual Meeting. . March 5-8, 2008 in Mont Tremblant,
Quebec.
59. Law G, Lalani S, Pope J, et al. The relationship between healthcare
access and disease activity and damage in a multiethnic cohort of systemic lupus
erythematosus (SLE) patients: The 1000 Canadian faces of lupus study. 2008. J Rheum
35(6):1195.
58. Law G, Lalani S, Pope J, et al. The relationship between healthcare
access and disease activity and damage in a multiethnic cohort of systemic lupus
erythematosus (SLE) patients: The 1000 Canadian Faces of lupus study: 2008. Arthritis
and Rheumatism 58 (9): S881
57. Lian J, Goyette P, Graham R, GenES Investigators,
Wither J, Fortin PR, Rioux J. A targeted association study in Systemic Lupus Erythematosus
(SLE) identifies novel risk alleles, and replicates known susceptibility alleles.
1st Annual Canadian Human Genetics Conference in St-Sauveur, Quebec, 2008.
56. Mittoo
S, Gelber A,, Hitchon CA, Silverman E, Pope JE, CaNIOS Investigators, Peschken C.
Predictors and Functional Impact of Lupus Lung Disease. Submitted to the American
College of Rheumatology Annual Scientific Meeting, San Francisco, Oct 24-29, 2008.
55. Akhavan PS, Neville C, Su J, Kassis J, Solymoss S, Pineau C, Peschken C, Pope
J, Boire G, Rauch J, Fortin PR. Vascular events in systemic lupus erythematosus
(SLE): evaluation of thrombophilic factors in a multicentre inception cohort (ThromboFIL).
Accepted for poster presentation at the American College of Rheumatology Annual
Scientific Meeting, San Francisco, Oct 24-29, 2008.
54. Al Dhanhani AM, Cymet A,
Harvey P, Da Costa D, Fortin PR. FMD measurement among lupus patients. Accepted
for poster presentation at the American College of Rheumatology Annual Scientific
Meeting, San Francisco, Oct 24-29, 2008.
53. HN Reich, SC Fan, J Su, JM Bargman,
J Wither, DD Gladman, MB Urowitz, AM Herzenberg, JW Scholey, DC Cattran and PR Fortin.
Important Predictors of CKD in an Inception Cohort of Patients with Lupus. Oral
Presentation at the American Society of Nephrology. Nov. 2008, Philadelphia, PA.
2007
52. Katz S, Pope J, Fortin PR, Silverman E, Chedeville G, Peschken C. 1000
Canadian faces of lupus: A look a the first year. Journal of Rheumatology, 2007;34(7)
1597.
51. Wither J, Cai Y, Lim S, McKenzie T, Su J, Claudio JO, CaNIOS GenES Investigators,
Cooper, G, Hudson T, Greenwood CMT, Fritzler M, Fortin PR. Increased Frequency of
Autoantibodies in the Family Members of Lupus Patients and Association with a Reduced
Proportion of NKT cells. Journal of Rheumatology, 2007;34(7) 1621.
50. Landolt-Morticorena
C, Ferguson C, Unnithan T, Gladman D, Urowitz M, Fortin PR, Wither J. Sustained
T cell activation promotes disease activity in lupus. Journal of Rheumatology, 2007;34(7)
1596.
49. Fortin PR, Cai Y, Lim S, McKenzie, T, Su, J. Claudio, JO, CaNIOS GenES
Investigators, Cooper GS, Hudson TJ, Greenwood, CMT, Wither, JE. Reduced proportions
of NKT cells in the relative of lupus patients and association with ANA. 8th International
Congress on SLE May 23-27, Shanghai, China.
48 Kassis J. Neville C, Rauch J, Solymoss
S, Joseph L, Belisle P, Fortin PR. Factors predictors of vascular events with antiphospholipids
antibodies. The American Society of Hematology, December 2007.
47. Landolt-Marticorena
C, Bonventi G , Cai Y, Unnithan T, Gladman D, Urowitz M, Fortin PR, and Wither JE.
Elevated BAFF Levels Correlate with Altered B Cell Phenotypes in Patients with Systemic
Lupus Erythematosus. Arthritis & Rheumatism 2007; (9suppl): F105.
46. Cooper
GS, Wither J, McKenzie T, Claudio JO, Hudson TJ, Greenwood CMT, Urowitz M, Pope
J, Bernatsky S, Smith CD, Hanly JG, Hitchon C, Boire G, CaNIOS Investigators, Fortin
PR. The Accuracy of Self-Reported History of Eleven Autoimmune Diseases. Arthritis
& Rheumatism 2007; (9suppl): S804
45. Tian YS, Shariati Z, Bobba R, Gladman
D, Urowitz M, Fortin PR. Anticardiolipin Antibodies are Associated with Higher Risk
of Thrombosis in Systemic Lupus Erythematosus: A Descriptive Study. Arthritis &
Rheumatism 2007; (9suppl): S1924
44. Tucker LB, Uribe A, Petty R., Silverman E.
Chedeville G., Huber AM, Peschken C, 1000 Canadian Faces of SLE Investigators. Pediatric
Systemic Lupus Erythematosus (SLE) in Canada: 1000 Canadian Faces of SLE Arthritis
& Rheumatism 2007; (9suppl): S881
43. Peschken CA, Pope J, Silverman E, Cooper
GS, The 1000 Canadian Faces of Lupus Investigators. Ethnic Differences in Patient
Perceptions of Systemic Lupus Erythematosus (SLE) Disease Activity in a Multiethnic
Cohort: The 1000 Canadian Faces of Lupus Study Arthritis & Rheumatism 2007;
(9suppl): S1110
42. Peschken CA, Pope J, Silverman E, Cooper GS, Katz S, The 1000
Canadian Faces of Lupus Investigators. The 1000 Canadian Faces of Lupus: A look
at the First Year Arthritis & Rheumatism 2007; (9suppl): S2160
2006
41. Kelly
E, McKenzie T, Chang N, Lim S, Harrison H, Hudson T, Cooper G, Greenwood C, Fortin
PR, Wither J. Evidence for abnormal B and T cell activation in lupus patients but
not their parents. Canadian Rheumatology Association. Acapulco, February 2006. (won
best student presentation).
40. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Pineau
C, Neville C, Esdaile J. Recent Corticosteroid Use and Recent Disease Activity:
Are They Independent Determinants of Coronary Heart Disease Risk Factors in Systemic
Lupus Erythematosus? Canadian Rheumatology Association. Acapulco, February 2006.
39. Bernatsky S, Clarke AE, Ramsey-Goldman R, Boivin JF, Joseph L, Gladman D, Urowitz
M, Fortin PR, Ginzler E, Manzi S, Gordon C, Bae SC, Barr SG, Edworthy S, Petri M,
Isenberg D, Rahman A, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M. Lung cancer
in systemic lupus erythematosus (SLE). 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st
Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals,
Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S280-S281 Suppl. S Sep 2006.
38.
Bernatsky S, Clarke AE, Gladman D, Urowitz M, Fortin PR, Barr SG, Senecal JL, Zummer
M, Edworthy S, Pope J, Ramsey-Goldman R, Hanly JG. Neuropsychiatric events in SLE:
Mortality related to cerebrovascular disease. 70th Annual Scientific Meeting of
the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals,
Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S281-S281 Suppl. S Sep 2006
37.
Wither JE, Chad L, Montpetit A, Montpetit A, Lim S, McKenzie T, Cooper S, Greenwood
CMT, Fortin PR, Hudson TJ. Genetic Association between LY9, a member of the SLAM
family, and systemic lupus erythematosus. 70th Annual Scientific Meeting of the
American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-
Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9):
S290-S291 Suppl. S Sep 2006
36. Wither JE, Cai YC, Lim S, McKenzie T, Su JD, Claudio
JO, Cooper GS, Hudson TJ, Greenwood CMT, Fritzler M, Fortin PR. Increased frequency
of autoantibodies in the family members of lupus patients and association with a
reduced proportion of NKT cells. 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st
Annual Scientific Meeting of the Association-Of-Rheumatology-Health-Professionals,
Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S291-S291 Suppl. S Sep 2006
35.
Bernatsky S, Clarke AE, Ramsey-Goldman R, Boivin JF, Joseph L, Urowitz M, Gladman
D, Fortin PR, Petri M, Girtzler E, Manzi S, Gordon C, Bae SC, Barr SG, Isenberg
D, Rahman A, Aranow C, Dooley MA, Senecal JL, Zummer M. Cancer Risk in SLE: No strong
evidence of an association with immunosuppressive drugs. 70th Annual Scientific
Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of
the Association-of-Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis
And Rheumatism 54 (9): S549-S550 Suppl. S Sep 2006
34. Fortin PR, Abrahamowicz M,
Cymet A, Neville C, Harvey P, Su J, Pineau c, Clarke AE, Bernatsky SR, Urowitz M,
Gladman D, Abbey, Holloway T, Huynh T, Da Costa D. The Health Improvement and Prevention
Program (HIPP) in systemic Lupus Erythematosus (SLE) shows preliminary benefits
in reducing the estimate 8-year-risk of cardiovascular disease. Arthritis &
Rheumatism 2006;54 (9 suppl) S791.
2005
33. Tisseverasinghe A, Fortin PR, Greenwood
C, Lim S, Su J. Association between serum total cholesterol and renal outcome in
systemic lupus erythematosus. Canadian Rheumatology Association Annual Meeting,
March 2-5, 2005, Mont Tremblant, Quebec.
32. Panopalis, P, Petri M, Manzi S, Isenberg
DA, Gordon C, Senecal J-L, Penrod JR, Joseph L, St. Pierre Y, Pineau C, Fortin PR,
Sutcliffe N, Goulet J-R, Choquette D, Grodzicky T, Esdaile JM, Clarke AE. American
patients experience greater productivity loss despite an increase use of health
care resources. Arthritis & Rheumatism 2005;52 (9 suppl) S401
31. Hanly J, Urowitz
M for the Systemic Lupus International Collaborating Clinics (SLICC). Neuropsychiatric
events at diagnosis of systemic lupus erythematosus. Arthritis & Rheumatism
2005;52 (9 suppl) S379.
30. Hanly J, Urowitz M for the Systemic Lupus International
Collaborating Clinics (SLICC). Attribution of neuorpsychiatric events at diagnosis
of systemic lupus erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S727.
29. Bobba R, Su J, Corey P, Shariati Z, Gladman D, Urowitz M, Fortin PR. The influence
of treatment of systemic lupus erythematosus (sle) with antimalarials or azatioprine
on the risk of thrombosis. Arthritis & Rheumatism 2005;52 (9 suppl) S727.
28.
Tisseverasinghe A, Bobba R, Su J, Corey P, Urowitz M, Gladman D, Fortin PR. Elevated
serum total cholesterol values are associated with poor renal outcome in systemic
lupus erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S465.
27. Urowitz
M, Gladman DD, Fortin PR, Sanchez-Guerrero J, Clarke AE, Bae SC, Gordon C, Isenberg
D, Hanly J, Merrill J, Ginzler E, Alarcon G, Wallace D, Petri M, Steinsson K, Dooley
MA, Manzi S, Bruce I Maddison P, Sturfelt G, Nived O, Zoma A, Aranow C, Ramsey-Goldman
R, van Vollenhoven R, Khamashta M. Systemic lupus international collaborating clinics
(SLICC) inception cohort registry to study risk factors for atherosclerosis (SLICC
RAS): First follow-up report. Arthritis & Rheumatism 2005;52 (9 suppl) S 608.
26. Bernatsky S, Boivin J-F, Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman R,
Clarke AE, Systemic Lupus International Collaborating Clinics (SLICC), Canadian
Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Mortality
in systemic lupus erythematosus: Risk according to cause, age, sex and lupus duration.
Arthritis & Rheumatism 2005;52 (9 suppl) S726.
25. Bernatsky S, Boivin J-F,
Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman R, Clarke AE, Systemic Lupus International
Collaborating Clinics (SLICC), Canadian Network for Improved Outcomes in Systemic
Lupus Erythematosus (CaNIOS). The Influence of Geographical and Racial/ethnic Factors
on Mortality Risk In Systemic Lupus Erythematosus. Arthritis & Rheumatism 2005;52
(9 suppl) S185.
24. Bernatsky S, Boivin J-F, Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman
R, Clarke AE, Systemic Lupus International Collaborating Clinics (SLICC), Canadian
Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Trends in
relative mortality rates for systemic lupus erythematosus over calendar time. Arthritis
& Rheumatism 2005;52 (9 suppl) S185.
23. Peschken CA, Katz SJ. Lupus and Ethnic
Minorities: Disease Outcomes in the Setting of a Universal Healthcare System. 69th
Annual Scientific Meeting Of The American- College-Of-Rheumatology/40th Annual Scientific
Meeting Of The Association-Of- Rheumatology-Health-Professionals, Nov 12-17, 2005
Arthritis And Rheumatism 52 (9): 420, Suppl. S Sep 2005
2004
22. Bernatsky S, Ramsey-Goldman
R, Boivin J-F, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman
D, Fortin PR, Petri M, Edworthy S, Gordon C, Bae S-C, Sibley J, Isenberg D, Aranow
C, Dooley M-A, Steinsson K, Nived O, Sturfelt G, Alarcon G, Clarke AE. An international
cohort study of cancer in systemic lupus erythematosus (SLE). Arthritis and Rheumatism
2004;50 (9 suppl)S592
2003
21. Bernatsky S, Ramsey-Goldman R, Boivin JF, Joseph
L, Rajan R, Zoma A, Manzi S, Urowitz M, Gladman D, Fortin PR, Gordon C, Bae SC,
Sibley J, Edworthy S, Barr SG, Isenberg D, Rahman A, El-Gabalawy H, Senecal JL,
Zummer M, Steinsson K, Hanly J, Pope J, Nived O, Clarke A. Cancer in Systemic Lupus
Erythematosus (SLE): An International Multi-Centre Cohort Study. Arthritis and Rheumatism
2003;48(9 suppl):S696.
20. Bernatsky S, Clarke A, Boivin JF, Joseph L, Rajan R,
Manzi S, Urowitz M, Gladman D, Fortin P, Gordon C, Bae SC, Sibley J, Edworthy S,
Barr S, Isenberg D, Rahman A, El- Gabalawy H, McCarthy T, Hanly J, Pope J, Sturfelt
G, Nived O, St.Pierre Y, Ramsey- Goldman R. Racial Factors Relating to Cancer Occurrence
in Systemic Lupus (SLE). Arthritis and Rheumatism 2003;48(9 suppl):S696.
2002
19.
Bernatsky S, Clarke A, Boivin JF, Joseph L, Rajan R, St. Pierre Y. Malignancy in
SLE: A Meta-Analysis (poster and oral presentation at NIH-sponsored meeting “SLE:
Targets for New Therapeutics,” Bethesda, 2002)
18. Bernatsky S, Clarke A, Boivin
JF, St. Pierre Y, Joseph L, Rajan R. The prevalence of risk factors for malignancy
in women with SLE. (SLE: Targets for New Therapeutics, Bethesda, 2002.
2001
17.
Chang ER, Fortin PR, Ferland D, Abrahamowicz M. The effect of organ system items
on the responsiveness of SLAM-R and SLEDAI to changes in disease activity relevant
to physicians and patients. Arthritis & Rheumatism 2000;43[9 suppl]:S148. (Note:
abstracts 4 and 5 were presented as one abstract at the Canadian Rheumatology Association
conference, Mont-Tremblant, February 2001, and at the Sixth International Lupus
Conference, Barcelona, March 2001)
16. Chang E, Abrahamowicz M, Ferland D, Fortin
PR. Overall and system-specific responsiveness of SLAM-R and SLEDAI to changes in
disease activity relevant to physicians and patients. Journal of Rheumatology 2001;28(6):12.
15. Chang E, Abrahamowicz M, Ferland D, Fortin PR. Overall and system-specific responsiveness
of SLAM-R and SLEDAI to changes in disease activity relevant to physicians and patients.
Lupus 2001;10(suppl);abstract #315, S109.
14. Fortin PR, Abrahamowicz M, Ferland
D, Lacaille D, Smith CD, Zummer M, CaNIOS. Study of methotrexate in lupus erythematosus
(SMILE): Significant decreased disease activity and steroid sparing effect in patients
without damage. Arthritis and Rheumatism 2001;44(9 suppl):S2004.
13. Chang ER, Abrahamowicz
M, Ferland D, Fortin PR. Subjective items contribute, independently of objective
items, to the responsiveness of SLAM-R to patient- and physician-reported changes
in SLE disease activity. Arthritis and Rheumatism 2001;44(9 suppl):S1160.
12. Bernatsky
S, Boivin J-F, Clarke A, Rajan R. Cancer risk in systemic lupus erythematosus: a
meta-analysis. Arthritis & Rheumatism 2001;44[9 suppl]:S244.
11. Bernatsky S,
Clarke A, St. Pierre Y, Boivin J-F, Joseph L, Rajan R. The prevalence of factors
influencing cancer risk in lupus: social habits, reproductive issues and obesity.
Arthritis & Rheumatism 2001;44[9 suppl]:S244.
10. Chang ER, Abrahamowicz M,
Ferland D, Fortin PR. Subjective items contribute, independently of objective items,
to the responsiveness of SLAM-R to patient- and physician-reported changes in SLE
disease activity. Arthritis & Rheumatism 2001;44[9 suppl], S246. 2001.
2000
9. Dobkin P, Clarke A, DaCosta D, & LEAP Group. Supportive-expressive group
psychotherapy for women with SLE: A Pan-Canadian randomized clinical trial. Journal
of Psychosomatic Research 2000;48:241.
8. Abrahamowicz M, Chang ER, Ferland D, Fortin
PR. Responsiveness of SLAM-R and SLEDAI to changes in SLE activity relevant to physicians
and patients. Arthritis & Rheumatism 2000;43[9 suppl]:S148.
7. Clarke A, Dobkin
P, Da Costa D, St. Pierre Y, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile
J, Beaulieu A, Senécal JL, Rich E, Choquette D, Goulet JR, Smith D, Cividino A,
Zummer M, Gladman D. A randomized multi-site controlled trial of group psychotherapy
for SLE. Arthritis & Rheumatism 2000;43(9 suppl):S149.
1999
6. Dobkin PL, Da
Costa D, Dritsa M, Fortin PR, Senécal JL, Goulet JR et al. Quality of life in SLE
during active and inactive disease states: Differential contributors to mental and
physical health. American Psychosomatic Society. Vancouver March 1,1999.
5. For
PR, Abrahamowicz M, Ferland D. Lupus disease activity measures are responsive to
change in the study of methotrexate in lupus erythematosus (SMILE). Arthritis &
Rheumatism 1999;42[9 suppl], S99.
1998
4. Ferland D, Clarke AE, Bélisle P, Joseph
L, Fortin PR. Later lupus flares over 4 years as predicted by activity and damage.
Lupus 1998;7(Suppl.):67.
3 Da Costa D, Pinard L, Dobkin PL, Clarke AE, Fortin PR,
Danoff DS, Esdaile JM. A prospective study on the role of stress in functional disability
among women with SLE. Lupus 1998;7(Suppl.):51.
2. Da Costa D, Clarke AE, Dobkin
PL, Senécal JL, Goulet JR, Choquette D, Grodzicky T, Fortin PR, Danoff DS, Esdaile
JM. Social support and health status influence satisfaction with medical care among
patients with systemic lupus erythematosus. Psychosomatic Medicine 1998;60:130.
1997
1. Dobkin PL, Clarke AE, Fortin PR, Esdaile JM, Danoff DS. Reducing distress
in systemic lupus erythematosus patients with group psychotherapy. Psychosomatic
Medicine 1997;59:77-108 (p.84-85)
|